Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amphastar Receives FDA Approval For Regadenoson Following Solid Q1

Multiple Pipeline Launches Expected For H2

Executive Summary

Amphastar has become the fifth firm to receive FDA approval for generic regadenoson, but the exact launch date for the firm and its other generic competitors remains uncertain.

You may also be interested in...



Amphastar’s Forteo ANDA Hit With CRL As Wait Goes On

Amphastar will not be receiving approval in 2022 for its proposed generic version of Eli Lilly’s Forteo (teriparatide) peptide for the treatment of osteoporosis, after the FDA told the company it could not issue an approval at this stage.

Amphastar Eyes Sun Pharma Showdown With US Ganirelix Approval

Amphastar is celebrating what it says is its fourth injectable peptide product approval from the USFDA with its generic version of Organon’s ganirelix acetate, in the process setting up a rivalry with Sun Pharma and commercial partner Ferring Pharmaceuticals.

US Needs OTC Inhalers For Asthma Treatment, And FDA Should Force A Switch, Researchers Say

In addition to epinephrine inhaler indicated for emergency use FDA currently allows for nonprescription access, a “positive step forward would be to make inhaled albuterol available OTC,” say researchers in a recent JAMA article.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel